Universal Beteiligungs und Servicegesellschaft mbH Reduces Position in Cencora, Inc. $COR

Universal Beteiligungs und Servicegesellschaft mbH cut its holdings in shares of Cencora, Inc. (NYSE:COR) by 3.0% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 168,959 shares of the company’s stock after selling 5,241 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Cencora were worth $57,113,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently modified their holdings of the company. Optima Capital LLC purchased a new stake in shares of Cencora during the fourth quarter valued at $31,000. IAG Wealth Partners LLC purchased a new stake in shares of Cencora during the third quarter valued at $30,000. Cloud Capital Management LLC purchased a new stake in shares of Cencora during the third quarter valued at $31,000. Caitlin John LLC purchased a new stake in shares of Cencora during the third quarter valued at $31,000. Finally, Harbor Investment Advisory LLC purchased a new stake in shares of Cencora during the fourth quarter valued at $35,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Leerink Partners reissued an “outperform” rating on shares of Cencora in a research report on Tuesday, March 17th. Robert W. Baird set a $415.00 target price on Cencora in a research report on Tuesday, January 13th. Weiss Ratings raised Cencora from a “hold (c+)” rating to a “buy (b)” rating in a research report on Thursday, February 5th. Morgan Stanley set a $380.00 target price on Cencora in a research report on Tuesday, March 17th. Finally, Wells Fargo & Company raised their target price on Cencora from $405.00 to $429.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 10th. Twelve research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $398.17.

Cencora Stock Down 1.5%

COR stock opened at $307.81 on Thursday. Cencora, Inc. has a twelve month low of $271.00 and a twelve month high of $377.54. The company has a quick ratio of 0.51, a current ratio of 0.92 and a debt-to-equity ratio of 3.62. The stock has a market cap of $59.88 billion, a P/E ratio of 37.00, a PEG ratio of 1.46 and a beta of 0.72. The business’s 50-day moving average price is $339.20 and its 200-day moving average price is $343.23.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.04 by $0.04. The company had revenue of $85.93 billion for the quarter, compared to the consensus estimate of $86.12 billion. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The firm’s quarterly revenue was up 5.5% on a year-over-year basis. During the same quarter last year, the company earned $3.73 EPS. On average, equities research analysts forecast that Cencora, Inc. will post 17.57 EPS for the current year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, March 2nd. Investors of record on Friday, February 13th were paid a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 0.8%. The ex-dividend date of this dividend was Friday, February 13th. Cencora’s dividend payout ratio (DPR) is 28.85%.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.